Imara

Imara, Inc. is dedicated to developing novel therapeutics for patients with sickle cell disease and other hemoglobinopathies. Imara is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. IMR-687 has been specifically designed to treat patients with sickle cell disease by both reducing red blood cell sickling and adherence of white blood cells to the blood vessel wall. These combined effects may lead to a lower occurrence of blockage of blood vessels that are underlying causes of the pathology of sickle cell disease. IMR-687 successfully completed a Phase 1 study in healthy volunteers and is currently being evaluated in a multi-national Phase 2a study in adult patients with sickle cell disease. Imara expects to broaden its development of IMR-687, with clinical trials of IMR-687 planned in pediatric patients with sickle cell disease as well as in patients with beta thalassemia, which is a group of genetic blood disorders that often leads to chronic anemia and other serious complications.